April 2021 Vol 7 No 2
By Kiana Wooten
In May 2019, Kiana Wooten went for a routine check-up. Read about how that routine visit turned into a breast cancer diagnosis for the 34-year-old Kiana, who had to be hospitalized during COVID-19. Read More ›
By Treven Pyles
Learning about lung cancer risks is important. An issue that needs more awareness is occupational exposure to harmful chemicals and the negative effects such exposure has on our health. Read More ›
The immunotherapy Libtayo received FDA approval as first-line treatment for patients with advanced or metastatic non–small-cell lung cancer and high PD-L1 expression. Read More ›
The immunotherapy Libtayo is a new treatment option for advanced or metastatic basal-cell carcinoma, a type of skin cancer. Libtayo was initially approved for a different type of skin cancer. Read More ›
Sabrina Steinback’s mom died from COVID-19 in 2020, and then Sabrina had a lumpectomy to remove breast cancer at the end of the year. Read More ›
Pepaxto is a novel therapy that has shown good results in multiple myeloma that does not respond to other therapies, according to myeloma expert Paul G. Richardson, MD, of Dana-Farber Cancer Institute. Read More ›
Abecma is the first gene therapy approved by the FDA for patients with multiple myeloma. It uses the patient’s own genetically modified T-cells to fight the cancer. Read More ›
Yescarta is the first CAR T-cell therapy approved by the FDA for patients with follicular lymphoma. It uses the patient’s own genetically modified T-cells to fight the cancer. Read More ›
Ukoniq is the first dual inhibitor of PI3K-delta and CK1-epsilon to be approved by the FDA, and is the first targeted, once-daily oral therapy option for marginal-zone or follicular lymphoma. Read More ›
“Today’s approval represents another milestone in the rapidly progressing field of gene therapy,” said Peter Marks, MD, PhD, Director of the FDA’s Center for Biologics Evaluation and Research. Read More ›